News Conference News TCT 2024 SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD L.A. McKeown October 29, 2024
News Conference News TCT 2023 Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door? L.A. McKeown October 24, 2023
News Daily News Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA L.A. McKeown July 11, 2023
News Conference News Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices L.A. McKeown November 18, 2022
News Conference News TCT 2022 RIVARAD: Rivaroxaban a Possible Solution to Radial Artery Occlusion Todd Neale September 21, 2022
News Daily News Routine IVUS in Peripheral Interventions Supported by Small RCT L.A. McKeown March 09, 2022
News Conference News VIVA 2021 EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions L.A. McKeown October 12, 2021
News Conference News VEITH 2019 More Real-world Data Support Safety of Paclitaxel-Based Devices in PAD L.A. McKeown November 22, 2019
News Conference News VIVA 2019 IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB L.A. McKeown November 05, 2019
News Conference News TCT 2019 ‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures L.A. McKeown September 28, 2019
News Daily News FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting L.A. McKeown June 10, 2019
News Daily News IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease L.A. McKeown January 25, 2019
News Daily News Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies L.A. McKeown January 23, 2019
News Conference News VIVA 2018 No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy L.A. McKeown November 13, 2018